

**REMARKS**

In view of the following remarks, the Examiner is respectfully requested to allow claims 149-153, 155 and 157-175 the only claims pending and currently under examination in this application.

**FORMAL MATTERS:**

Claims 149-153, 155 and 157-175 are pending after entry of the amendments set forth herein.

Please cancel claims 154 and 156 without prejudice or disclaimer. Claims 149, 151, 152, 155 and 157 are amended. Claims 151 and 152 are amended to correct a spelling error. Claims 155 and 157 are amended to correct dependency after cancelation of a claim. Support for the amendment to Claim 149 is found at least in original Claim 154 and in the specification at least at page 20, paragraph [0094].

The Applicants assert these amendments add no new matter and their entry is respectfully requested.

CONCLUSION

Applicants submit that all of the claims are in condition for allowance, which action is requested. If the Examiner finds that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at (510) 923-2438.


The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-4409.

Respectfully submitted,

Customer No. 75074

April 28, 2010  
Novartis Vaccines and Diagnostics, Inc.  
Intellectual Property  
P.O. Box 8097  
Emeryville, California 94662-8097  
(510) 923-2438  
(510) 655-3542 (fax)

By:



David A. Carpenter  
Attorney for Applicants  
Reg. No. 45,945